Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.67 |
| ▸ | ERBB2 | P04626 | 16/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.65 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.65 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.65 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.65 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.65 |
| ▸ | STK10 | O94804 | 1/20 | 0.65 |
| ▸ | ABL1 | P00519 | 1/20 | 0.65 |
| ▸ | INSR | P06213 | 1/20 | 0.65 |
| ▸ | RET | P07949 | 1/20 | 0.65 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.65 |
| ▸ | SRC | P12931 | 1/20 | 0.65 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.65 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.65 |
| ▸ | CDK2 | P24941 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5064133 | 0.95 | EGFR (0.66) | EGFRERBB2MEN1KMT2AMAPK1 | |
| SCHEMBL5061181 | 0.91 | EGFR (0.62) | EGFRERBB2MEN1KMT2AMAPK1 | |
| SCHEMBL5061534 | 0.89 | EGFR (0.56) | EGFRERBB2 | |
| SCHEMBL5061256 | 0.89 | EGFR (0.57) | EGFRERBB2 | |
| SCHEMBL5065393 | 0.88 | EGFR (0.55) | EGFRERBB2MEN1KMT2AMAPK1 | |
| SCHEMBL5064147 | 0.88 | EGFR (0.55) | EGFRERBB2 | |
| SCHEMBL5068838 | 0.87 | EGFR (0.54) | EGFRERBB2 | |
| SCHEMBL5061266 | 0.86 | EGFR (0.61) | EGFRERBB2MEN1KMT2AMAPK1 | |
| SCHEMBL5065486 | 0.84 | EGFR (0.56) | EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL5061417 | 0.84 | EGFR (0.56) | EGFRERBB2ABL1INSRPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269238-A1 | Thiazolopyrimidine Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | claimed |
| EP-1731523-A1 | THIAZOLOPYRIMIDINE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2006-12-13 | — | — | EP | claimed |
| US-20080269238-A1 | Thiazolopyrimidine Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| US-20080269238-A1 | Thiazolopyrimidine Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| US-20080269238-A1 | Thiazolopyrimidine Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1731523-A1 | THIAZOLOPYRIMIDINE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2006-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269238-A1 | Thiazolopyrimidine Derivative | FGFR3, FGFR1, ERBB3 | EGFR 28/4885ERBB2 8/4885MEN1 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.